Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

cardiometabolic diseases

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

- PMLiVE

Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

Inizio

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

Growth driven by increased sales in diabetes and obesity markets

- PMLiVE

Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations

The transition will help the company meet the rising global demand in the obesity market

- PMLiVE

Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

The company is planning to submit the candidate for regulatory review by the end of the year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links